FierceBiotech Jan 5, 2026 Cash-strapped TME Pharma loses partner, prompting eye drug strategy rethink
FierceBiotech Jan 5, 2026 Insilico, fresh off its Hong Kong IPO, pens potential $888M cancer R&D pact with Servier
FierceBiotech Jan 2, 2026 Cellular energy booster restores cognition in mice with advanced Alzheimer’s disease
FierceBiotech Jan 2, 2026 NIH instability grows with exit of neuro director, leaving half of institutes under interim leadership
FierceBiotech Jan 2, 2026 Sanofi, Corcept surprised by FDA rejections for MS, Cushing's syndrome drugs
FierceBiotech Jan 2, 2026 Neuralink to kick-start 'high-volume production' of brain-computer interface devices, Elon Musk says
FierceBiotech Jan 2, 2026 Neuro biotech Nido closes after phase 2 study fails to move needle in rare disease
FierceBiotech Jan 2, 2026 AbbVie, Gilead gift themselves clinical-stage cancer drugs via licensing deals
FierceBiotech Jan 2, 2026 Biohaven flunks phase 2 depression trial, adding to concerns for pivotal epilepsy readout
FierceBiotech Jan 2, 2026 Ultragenyx plans major cost-cutting push after flunking phase 3 brittle bone trials
FierceBiotech Dec 31, 2025 Quanterix's blood test for Alzheimer's disease uncovers potentially treatable population in decades-long study
FierceBiotech Dec 30, 2025 Breast cancer tops list of most-studied diseases for 5th year in a row: report